HUE055594T2 - Mutáns Clostridium difficile toxinhoz kapcsolódó készítmények és eljárások - Google Patents

Mutáns Clostridium difficile toxinhoz kapcsolódó készítmények és eljárások

Info

Publication number
HUE055594T2
HUE055594T2 HUE13786535A HUE13786535A HUE055594T2 HU E055594 T2 HUE055594 T2 HU E055594T2 HU E13786535 A HUE13786535 A HU E13786535A HU E13786535 A HUE13786535 A HU E13786535A HU E055594 T2 HUE055594 T2 HU E055594T2
Authority
HU
Hungary
Prior art keywords
compositions
clostridium difficile
difficile toxin
methods relating
mutant clostridium
Prior art date
Application number
HUE13786535A
Other languages
English (en)
Hungarian (hu)
Inventor
Kathrin Ute Jansen
Annaliesa Sybil Anderson
Robert G K Donald
Michael James Flint
Narender Kumar Kalyan
Jason Arnold Lotvin
Maninder K Sidhu
Justin Keith Moran
Mark Edward Ruppen
Weiqiang Sun
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HUE055594T2 publication Critical patent/HUE055594T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE13786535A 2012-10-21 2013-10-07 Mutáns Clostridium difficile toxinhoz kapcsolódó készítmények és eljárások HUE055594T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261716605P 2012-10-21 2012-10-21

Publications (1)

Publication Number Publication Date
HUE055594T2 true HUE055594T2 (hu) 2021-12-28

Family

ID=49546596

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13786535A HUE055594T2 (hu) 2012-10-21 2013-10-07 Mutáns Clostridium difficile toxinhoz kapcsolódó készítmények és eljárások

Country Status (19)

Country Link
US (5) US10787652B2 (enExample)
EP (2) EP3912990A1 (enExample)
JP (4) JP6527661B2 (enExample)
KR (5) KR101940939B1 (enExample)
CN (2) CN104797706B (enExample)
AU (5) AU2013333532C1 (enExample)
BR (2) BR122016023101B1 (enExample)
CA (2) CA2887891C (enExample)
DK (1) DK2909307T3 (enExample)
ES (1) ES2878551T3 (enExample)
HR (1) HRP20211170T1 (enExample)
HU (1) HUE055594T2 (enExample)
IL (3) IL237792B (enExample)
MX (2) MX369289B (enExample)
PL (1) PL2909307T3 (enExample)
PT (1) PT2909307T (enExample)
RU (1) RU2630671C2 (enExample)
SI (1) SI2909307T1 (enExample)
WO (1) WO2014060898A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
WO2016131157A1 (en) * 2015-02-19 2016-08-25 Immune Biosolutions Inc Clostridium difficile toxins a and/or b antigen and epitope antibody, and pharmaceutical uses thereof
KR101723167B1 (ko) * 2015-04-28 2017-04-05 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
KR101729251B1 (ko) * 2015-04-28 2017-04-21 주식회사 대웅 보툴리눔 독소의 제조를 위한 배지 조성물
WO2017040885A1 (en) * 2015-09-03 2017-03-09 The Board Of Regents Of The University Of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
EP3558363A1 (en) 2016-12-21 2019-10-30 Amgen Inc. Anti-tnf alpha antibody formulations
CN106801077A (zh) * 2017-02-13 2017-06-06 江南大学 一种高效杀灭滴虫等医学原虫的细菌培养上清液的制备方法和及其利用
IL320444A (en) * 2017-09-28 2025-06-01 Pfizer Compositions and methods for stimulating an immune response against Clostridium difficile
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
MX2021014097A (es) * 2019-05-21 2022-03-11 Univ California Composiciones de vacunas para clostridium difficile.
EP4146200A4 (en) * 2020-05-06 2024-05-15 Albert Einstein College of Medicine AGENTS FOR PREVENTING TISSUE DAMAGE RELATED TO CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITING THE BACTERIAL TOXINS TCDA AND TCDB DAMAGED THE INTESTIN
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CA3254452A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. ADJUVANT PRODUCTION PROCESSES
CN120475988A (zh) 2022-12-13 2025-08-12 辉瑞公司 免疫原性组合物及引发针对艰难梭菌的免疫应答的方法
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
WO2025257712A1 (en) 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4530833A (en) * 1982-09-13 1985-07-23 Wilkins Tracy D Toxins and antibodies of C. difficile
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
EP0154064A1 (en) * 1984-03-02 1985-09-11 Tracy Dale Wilkins Toxins and antibodies of C. difficile
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
JPH06509866A (ja) 1991-04-22 1994-11-02 マサチューセッツ　ヘルス　リサーチ　インスティチュート，インコーポレーテッド 呼吸系ウイルスに対する有効な抗体力価用の血漿試料をスクリーニングする方法
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
JP4129544B2 (ja) 1993-03-29 2008-08-06 ファイザー・インク サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
BR9509903A (pt) 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
DE69610106D1 (de) 1995-07-07 2000-10-05 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
JPH11510793A (ja) 1995-07-07 1999-09-21 オラバックス インク． 胃腸病に対する鼻腔内ワクチン接種
CA2232001C (en) 1995-09-15 2002-12-10 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
ATE272409T1 (de) 1996-09-30 2004-08-15 Univ Arkansas Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
JP2002541808A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
PL365453A1 (en) 2000-05-04 2005-01-10 President And Fellows Of Harvard College Compounds and methods for the treatment and prevention of bacterial infection
DE60217107T2 (de) 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2004041857A2 (en) 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
PL1709170T3 (pl) 2004-01-16 2018-06-29 Pfenex Inc. Ekspresja białek ssaczych w Pseudomonas fluorescens
NZ530709A (en) * 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
JP4588763B2 (ja) 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
WO2006071877A2 (en) 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
MXPA06009853A (es) * 2005-03-03 2007-03-29 Allergan Inc Medios para bacteria de clostridium y procesos para obtener una toxina clostridial.
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) * 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
WO2007090126A2 (en) 2006-01-30 2007-08-09 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
US20080206819A1 (en) 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
EP2813144A1 (en) * 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
US9023352B2 (en) 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
CN101855336B (zh) 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
WO2009132082A2 (en) 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US8206940B2 (en) 2008-05-15 2012-06-26 Tufts University Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression
WO2009156852A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
US9115347B2 (en) * 2008-09-24 2015-08-25 Sanofi Pasteur Biologies, LLC Methods and compositions for increasing toxin production
US8444996B2 (en) * 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
SG171934A1 (en) 2008-12-03 2011-07-28 Boehringer Ingelheim Vetmed Process for production of vaccines
EP2376107B1 (en) 2008-12-09 2014-05-21 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
GB0901001D0 (en) 2009-01-22 2009-03-04 Univ Nottingham Methods
EP2405940B1 (en) 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
WO2011060431A2 (en) 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
AU2010325992A1 (en) 2009-12-02 2012-05-31 Tufts University Atoxic recombinant holotoxins of Clostridium difficile as immunogens
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
US8530171B2 (en) * 2010-03-30 2013-09-10 Pfenex Inc. High level expression of recombinant toxin proteins
US8765399B2 (en) * 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
WO2012028418A1 (en) * 2010-09-02 2012-03-08 Novacem Limited Integrated process for producing compositions containing magnesium
JP6121421B2 (ja) * 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012078313A2 (en) 2010-11-12 2012-06-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
CN102533867A (zh) * 2010-12-10 2012-07-04 西北民族大学 一种艰难梭菌a毒素的类毒素的制备方法
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US9290565B2 (en) * 2011-05-27 2016-03-22 Glaxosmithkline Biologicals, S.A. Immunogenic composition
WO2012166991A1 (en) 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
WO2013082298A2 (en) * 2011-11-30 2013-06-06 Board Of Trustees Of Michigan State University Immunological composition for clostridium difficile
CN103974718A (zh) * 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
MX2015002485A (es) * 2012-09-19 2015-06-05 Novartis Ag Polipeptidos de clostridium difficile como vacuna.
BR122016023101B1 (pt) * 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US10117933B2 (en) * 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
LT2928489T (lt) * 2012-12-05 2019-04-10 Glaxosmithkline Biologicals S.A. Imunogeninė kompozicija
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014144292A2 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
JP2016516721A (ja) * 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
US20170165375A1 (en) 2013-04-02 2017-06-15 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
EP3060246A4 (en) * 2013-10-23 2017-08-16 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10947494B2 (en) 2015-11-17 2021-03-16 Pfizer Inc. Media and fermentation methods for producing polysaccharides in bacterial cell culture
US10813988B2 (en) * 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
IL269258B2 (en) 2017-03-15 2023-09-01 Novavax Inc Methods and compositions for inducing immune responses against Clostridium difficile
CA3016351A1 (en) 2017-09-05 2019-03-05 Mcmaster University Aptamers for clostridium difficile detection
IL320444A (en) 2017-09-28 2025-06-01 Pfizer Compositions and methods for stimulating an immune response against Clostridium difficile
WO2020201985A1 (en) 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Also Published As

Publication number Publication date
JP2023036952A (ja) 2023-03-14
JP2021119775A (ja) 2021-08-19
US20200165582A1 (en) 2020-05-28
IL284582B (en) 2022-12-01
JP6527661B2 (ja) 2019-06-05
US20250002875A1 (en) 2025-01-02
US11208633B2 (en) 2021-12-28
CN108004286A (zh) 2018-05-08
AU2013333532B2 (en) 2016-11-24
US20190112584A1 (en) 2019-04-18
IL284582A (en) 2021-08-31
CN108004286B (zh) 2022-03-08
HK1254448A1 (zh) 2019-07-19
US11952597B2 (en) 2024-04-09
JP7208293B2 (ja) 2023-01-18
BR112015008844A8 (pt) 2018-04-03
KR101940939B1 (ko) 2019-01-21
EP2909307A2 (en) 2015-08-26
AU2013333532C1 (en) 2019-10-24
BR122016023101A2 (pt) 2019-08-27
SI2909307T1 (sl) 2021-08-31
KR20170077263A (ko) 2017-07-05
AU2019203159B2 (en) 2020-05-07
CA3063892C (en) 2023-05-09
KR20190069604A (ko) 2019-06-19
AU2017201193A1 (en) 2017-03-16
PL2909307T3 (pl) 2022-11-07
KR20150056843A (ko) 2015-05-27
US10787652B2 (en) 2020-09-29
KR102169216B1 (ko) 2020-10-22
KR20200017552A (ko) 2020-02-18
IL271064A (en) 2020-01-30
BR112015008844A2 (pt) 2017-11-21
KR101990272B1 (ko) 2019-06-17
EP3912990A1 (en) 2021-11-24
AU2019203159A1 (en) 2019-05-30
AU2013333532A1 (en) 2015-04-02
AU2021277590A1 (en) 2021-12-23
CA3063892A1 (en) 2014-04-24
RU2015112079A (ru) 2016-12-10
MX379863B (es) 2025-03-11
WO2014060898A3 (en) 2014-06-12
MX2015004986A (es) 2015-07-17
CN104797706A (zh) 2015-07-22
KR20190008988A (ko) 2019-01-25
CA2887891A1 (en) 2014-04-24
BR122016023101B1 (pt) 2022-03-22
US20150291940A1 (en) 2015-10-15
AU2020203423A1 (en) 2020-06-11
HK1212385A1 (en) 2016-06-10
EP2909307B1 (en) 2021-05-26
CA2887891C (en) 2023-03-07
KR101751822B1 (ko) 2017-06-28
KR102078517B1 (ko) 2020-02-18
JP2014083054A (ja) 2014-05-12
AU2017201193C1 (en) 2019-10-24
IL237792A0 (en) 2015-05-31
MX2019013075A (es) 2019-12-16
DK2909307T3 (da) 2021-07-05
US20210024903A1 (en) 2021-01-28
US10982198B2 (en) 2021-04-20
RU2630671C2 (ru) 2017-09-11
JP6871969B2 (ja) 2021-05-19
WO2014060898A2 (en) 2014-04-24
JP2019150045A (ja) 2019-09-12
IL284582B2 (en) 2023-04-01
MX369289B (es) 2019-11-04
IL237792B (en) 2021-03-25
PT2909307T (pt) 2021-07-14
AU2017201193B2 (en) 2019-02-07
HRP20211170T1 (hr) 2021-11-12
IL271064B (en) 2021-07-29
ES2878551T3 (es) 2021-11-19
JP7556987B2 (ja) 2024-09-26
CN104797706B (zh) 2020-05-26
BR112015008844B1 (pt) 2022-03-22

Similar Documents

Publication Publication Date Title
IL284582A (en) Compositions and methods related to mutant Clostridium difficile toxin
IL273231B (en) Clostridium difficile toxin-related preparations and methods
IL236158A0 (en) Methods and compositions to create biomethane
PT3564357T (pt) Bacterioterapia para colite por clostridium difficile
SG11201406301TA (en) Clostridium difficile antigens
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
HUE049421T2 (hu) Clostridium difficile dehidrogenáz és toxin mint biomarker
SG11201501176UA (en) Compositions and methods for detection of clostridium difficile